Literature DB >> 25389366

CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice.

Guangzhi Chen1, Renfan Xu2, Shasha Zhang1, Yinna Wang1, Peihua Wang1, Matthew L Edin3, Darryl C Zeldin3, Dao Wen Wang4.   

Abstract

Cytochrome P-450 epoxygenase-derived epoxyeicosatrienoic acids (EETs) exert diverse biological activities, which include potent vasodilatory, anti-inflammatory, antiapoptotic, and antioxidatant effects, and cardiovascular protection. Liver has abundant epoxygenase expression and high levels of EET production; however, the roles of epoxygenases in liver diseases remain to be elucidated. In this study, we investigated the protection against high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in mice with endothelial-specific CYP2J2 overexpression (Tie2-CYP2J2-Tr). After 24 wk of high-fat diet, Tie2-CYP2J2-Tr mice displayed attenuated NAFLD compared with controls. Tie2-CYP2J2-Tr mice showed significantly decreased plasma triglyceride levels and liver lipid accumulation, improved liver function, reduced inflammatory responses, and less increase in hepatic oxidative stress than wild-type control mice. These effects were associated with inhibition of NF-κB/JNK signaling pathway activation and enhancement of the antioxidant defense system in Tie2-CYP2J2-Tr mice in vivo. We also demonstrated that 14,15-EET treatment protected HepG2 cells against palmitic acid-induced inflammation and oxidative stress. 14,15-EET attenuated palmitic acid-induced changes in NF-κB/JNK signaling pathways, malondialdehyde generation, glutathione levels, reactive oxygen species production, and NADPH oxidase and antioxidant enzyme expression in HepG2 cells in vitro. Together, these results highlight a new role for CYP epoxygenase-derived EETs in lipotoxicity-related inflammation and oxidative stress and reveal a new molecular mechanism underlying EETs-mediated anti-inflammatory and antioxidant effects that could aid in the design of new therapies for the prevention and treatment of NAFLD.

Entities:  

Keywords:  CYP2J2; EETs; inflammation; nonalcoholic fatty liver disease; oxidative stress; palmitic acid

Mesh:

Substances:

Year:  2014        PMID: 25389366      PMCID: PMC4297779          DOI: 10.1152/ajpendo.00366.2014

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  46 in total

Review 1.  The role of oxidative stress in non-alcoholic steatohepatitis.

Authors:  G H Koek; P R Liedorp; A Bast
Journal:  Clin Chim Acta       Date:  2011-04-16       Impact factor: 3.786

Review 2.  Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis.

Authors:  Anabela P Rolo; João S Teodoro; Carlos M Palmeira
Journal:  Free Radic Biol Med       Date:  2011-10-13       Impact factor: 7.376

3.  PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver.

Authors:  Mohamed A Abdelmegeed; Seong-Ho Yoo; Lauren E Henderson; Frank J Gonzalez; Kimberley J Woodcroft; Byoung-Joon Song
Journal:  J Nutr       Date:  2011-02-23       Impact factor: 4.798

4.  Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced diabetic mice.

Authors:  Guangzhi Chen; Peihua Wang; Gang Zhao; Gang Xu; Artiom Gruzdev; Darryl C Zeldin; Dao Wen Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-06-30       Impact factor: 3.072

5.  Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.

Authors:  Lars P Bechmann; Peri Kocabayoglu; Jan-Peter Sowa; Svenja Sydor; Jan Best; Martin Schlattjan; Anja Beilfuss; Johannes Schmitt; Rebekka A Hannivoort; Alpaslan Kilicarslan; Christian Rust; Frieder Berr; Oliver Tschopp; Guido Gerken; Scott L Friedman; Andreas Geier; Ali Canbay
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

6.  Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice.

Authors:  Liang Li; Lei Chen; Liang Hu; Yuan Liu; Han-Yong Sun; Jing Tang; Yu-Jie Hou; Yan-Xin Chang; Qian-Qian Tu; Gen-Sheng Feng; Feng Shen; Meng-Chao Wu; Hong-Yang Wang
Journal:  Hepatology       Date:  2011-07-25       Impact factor: 17.425

Review 7.  Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.

Authors:  Briohny W Smith; Leon A Adams
Journal:  Nat Rev Endocrinol       Date:  2011-05-10       Impact factor: 43.330

Review 8.  Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities.

Authors:  Roberto Gambino; Giovanni Musso; Maurizio Cassader
Journal:  Antioxid Redox Signal       Date:  2011-04-20       Impact factor: 8.401

9.  Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1.

Authors:  Michael Potente; U Ruth Michaelis; Beate Fisslthaler; Rudi Busse; Ingrid Fleming
Journal:  J Biol Chem       Date:  2002-02-26       Impact factor: 5.157

10.  Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide.

Authors:  Liu Liu; Chen Chen; Wei Gong; Yuanjing Li; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-08-16       Impact factor: 4.030

View more
  15 in total

Review 1.  The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.

Authors:  Xizhen Xu; Rui Li; Guangzhi Chen; Samantha L Hoopes; Darryl C Zeldin; Dao Wen Wang
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

Review 2.  Soluble epoxide hydrolase as a therapeutic target for obesity-induced disorders: roles of gut barrier function involved.

Authors:  Jianan Zhang; Maolin Tu; Zhenhua Liu; Guodong Zhang
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2020-09-19       Impact factor: 4.006

3.  CYP2J2 overexpression ameliorates hyperlipidemia via increased fatty acid oxidation mediated by the AMPK pathway.

Authors:  Shasha Zhang; Guangzhi Chen; Ning Li; Meiyan Dai; Chen Chen; Peihua Wang; Huiru Tang; Samantha L Hoopes; Darryl C Zeldin; Dao Wen Wang; Xizhen Xu
Journal:  Obesity (Silver Spring)       Date:  2015-06-05       Impact factor: 5.002

4.  Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.

Authors:  Clothilde Roche; Dominique Guerrot; Najah Harouki; Thomas Duflot; Marie Besnier; Isabelle Rémy-Jouet; Sylvanie Renet; Anaïs Dumesnil; Annie Lejeune; Christophe Morisseau; Vincent Richard; Jeremy Bellien
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-05-27       Impact factor: 3.072

5.  Inhibition of soluble epoxide hydrolase ameliorates hyperhomocysteinemia-induced hepatic steatosis by enhancing β-oxidation of fatty acid in mice.

Authors:  Liu Yao; Boyang Cao; Qian Cheng; Wenbin Cai; Chenji Ye; Jing Liang; Wenli Liu; Lu Tan; Meng Yan; Bochuan Li; Jinlong He; Sung Hee Hwang; Xu Zhang; Chunjiong Wang; Ding Ai; Bruce D Hammock; Yi Zhu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-02-21       Impact factor: 4.052

6.  Ablation of soluble epoxide hydrolase reprogram white fat to beige-like fat through an increase in mitochondrial integrity, HO-1-adiponectin in vitro and in vivo.

Authors:  Lu Liu; Nitin Puri; Marco Raffaele; Joseph Schragenheim; Shailendra P Singh; J Alyce Bradbury; Lars Bellner; Luca Vanella; Darryl C Zeldin; Jian Cao; Nader G Abraham
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-07-21       Impact factor: 3.072

7.  CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity.

Authors:  Eric A Evangelista; Rozenn N Lemaitre; Nona Sotoodehnia; Sina A Gharib; Rheem A Totah
Journal:  Drug Metab Dispos       Date:  2018-01-17       Impact factor: 3.922

Review 8.  Targeting the eicosanoid pathway in hepatocellular carcinoma.

Authors:  Anshuli Razdan; Nathan M Main; Vincent Chiu; Nicholas A Shackel; Paul de Souza; Katherine Bryant; Kieran F Scott
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

9.  11,12-Epoxyecosatrienoic acids mitigate endothelial dysfunction associated with estrogen loss and aging: Role of membrane depolarization.

Authors:  Chongxiu Sun; Scott I Simon; Greg A Foster; Christopher E Radecke; HyunTae V Hwang; Xiaodong Zhang; Bruce D Hammock; N Chiamvimonvat; Anne A Knowlton
Journal:  J Mol Cell Cardiol       Date:  2016-04-11       Impact factor: 5.000

10.  Linoleic Acid-Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol-Associated Liver Injury.

Authors:  Dennis Warner; Vatsalya Vatsalya; Kara H Zirnheld; Jeffrey B Warner; Josiah E Hardesty; John C Umhau; Craig J McClain; Krishnarao Maddipati; Irina A Kirpich
Journal:  Hepatol Commun       Date:  2021-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.